Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference
LYON, France and CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen ,
View HTML
Toggle Summary ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service
Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics LYON, France and CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2020
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer Trial in Progress Poster selected for inclusion in Poster Walk LYON, France and CAMBRIDGE, Mass. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Mar 16, 2020

Business Update and Financial Highlights for the 4th Quarter and Full Year of 2019 (after U.S. market close)

Summary Toggle Mar 17, 2020 at 8:30 AM EDT

Erytech Pharma 4th Quarter and Full Year of 2019 Conference Call and Webcast

Summary Toggle May 6, 2020

Business Update and Financial Highlights for the 1st Quarter of 2020 (after U.S. market close)

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top